Search results
Professor of Pediatrics. The Walensky laboratory focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer. Our goal is to develop an arsenal of new compounds-a “chemical toolbox”-to investigate and block protein interactions that cause cancer.
Email: loren_walensky@dfci.harvard.edu. Website: http://www.hms.harvard.edu/dms/bbs/fac/walensky.php Lab Size: 15-20. Summary. The Walensky laboratory focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer.
Loren David Walensky. The Walensky laboratory focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer. Our goal is to develop an arsenal of new compounds-a “chemical toolbox”-to investigate and block protein interactions that cause cancer.
Walensky is currently Principal Investigator and Attending Physician in the Department of Pediatric Oncology at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Professor Pediatrics at Harvard Medical School; and Director of the Harvard/MIT MD-PhD Program.
May 1, 2019 · Loren David Walensky, M.D., Ph.D. Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice. Authors: Authors: Mourtada R, Herce HD, Yin DJ, Moroco JA, Wales TE, Engen JR, Walensky LD. Targeting BAX to drug death directly.
25 Shattuck Street Boston, MA 02115 CSS Styles Code. fcf2c6b74fbdd7d4cf432a1c39a278f0
486. 2010. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. GL Verdine, LD Walensky. Clinical cancer research 13 (24), 7264-7270. , 2007. 475. 2007. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
